Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma

✍ Scribed by Michel Delforge; Evangelos Terpos; Paul G. Richardson; Ofer Shpilberg; Nuriet K. Khuageva; Rudolf Schlag; Meletios A. Dimopoulos; Martin Kropff; Ivan Spicka; Maria T. Petrucci; Olga S. Samoilova; Maria-Victoria Mateos; Hila Magen-Nativ; Hartmut Goldschmidt; Dixie-Lee Esseltine; Deborah S. Ricci; Kevin Liu; William Deraedt; Andrew Cakana; Helgi van de Velde; Jesús F. San Miguel

• Book ID: 114794922
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 364 KB
• Volume: 86
• Category: Article
• ISSN: 0902-4441
• DOI: 10.1111/j.1600-0609.2011.01599.x